Your browser doesn't support javascript.
loading
Treatment of candidemia with echinocandins: data on hospital resource use from a real world setting.
Wade, Rolin L; Chaudhari, Paresh; Campbell, Rebecca S; Hays, Harlen D; Nathanson, Brian H; Yi, Jing; Horn, David.
Afiliação
  • Wade RL; Cerner LifeSciences, Culver City, CA 90230, USA. rolin.wade@cerner.com
J Med Econ ; 15(6): 1130-8, 2012.
Article em En | MEDLINE | ID: mdl-22788668
ABSTRACT

OBJECTIVE:

Real-world data on patients treated with echinocandins for candidemia are limited. This study examined the effect of three echinocandin-based treatment regimens on resource utilization in patients with Candida infection. RESEARCH DESIGN AND

METHODS:

A retrospective cohort study of patients hospitalized between 2005 and 2010 with a blood culture positive for Candida. Length of stay (LOS) following AF initiation (post-AF LOS) and total days with AF treatment were compared in patients treated with three different echinocandin regimens patients with echinocandin only, patients who received fluconazole prior to an echinocandin (fluconazole-echinocandin), and patients who received an echinocandin prior to fluconazole (echinocandin-fluconazole). Generalized linear models were used to adjust for confounders.

RESULTS:

A total of 647 patients met inclusion criteria. Patients treated with echinocandin only were more acutely ill, having more organ dysfunction and sepsis. Unadjusted post-AF LOS was significantly greater in the groups that received both echinocandin and fluconazole (mean, 13.1 days for echinocandin-only vs 25.5 and 21.2 days for fluconazole-echinocandin and echinocandin-fluconazole groups, respectively, p<0.001). These groups also had a higher total number of days with AF orders. These differences remained after multivariate adjustment and in survivor-only analyses. Compared with echinocandin-only treatment, the average marginal effect of fluconazole-echinocandin and echinocandin-fluconazole regimens were associated with significantly longer adjusted post-AF LOS (by 7.2 days and 9.3 days, respectively, p<0.001) and significantly more adjusted total AF days (by 5.3 days for fluconazole-echinocandin and 6.5 days for echinocandin-fluconazole patients, p<0.001). Limitations included lack of visibility to specific reasons for therapy changes.

CONCLUSIONS:

Fluconazole before or after echinocandin was associated with significantly greater resource utilization than echinocandin use alone.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fluconazol / Preços Hospitalares / Equinocandinas / Candidemia / Antifúngicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Med Econ Ano de publicação: 2012 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fluconazol / Preços Hospitalares / Equinocandinas / Candidemia / Antifúngicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Med Econ Ano de publicação: 2012 Tipo de documento: Article